ATP6V0D2 and glioblastoma: RPL41, RPL36A, MRPL30, MRPL35, MRPS17, MRPL20, RPL26L1, MRPS31, MRRF, MRPL58, MRPL40, NDUFA9, and ATP6V0D2 were identified as novel biomarkers for the pathogenesis of GBM.